Oncosec is simply focused on the PISCES trial right now. With other trials set to start soon, I think presenting positive data at SITC will set the stage for strong momentum heading into 2019. The multi-gene candidate will be revealed. Head and Neck trial will start as well as a trial with Opdivo in melanoma. TNBC combo trial will likely start by end of this month.I think alot of things will start to unfold after SITC. Oncosec will probably present a late-breaking abstract like last year. I will be interested to hear any more news with the Avacta collaboration.